DEVELOPMENT OF A SET OF PROPOSALS TO IMPROVE USER INTERACTION WITH THE SITE OF ONLINE PHARMACIES

Purpose of the study: develop a set of proposals to improve user interaction with the Internet pharmacy website. Methods. The study used the methods of logical, comparative, structural and content anal- ysis. Results. A set of proposals has been formulated to improve user interaction with the web- site of online pharmacies, including: an indication of the actual expiration date of available drugs, an indication of a public offer and a license, information that the site is not an aggregator, information on labeling, and opportunities: the choice of analogues of a drug with taking into account their cost, online consultations with a pharmaceutical / medical professional, feedback, the ability to assess the pharma- cological compatibility of purchased / or used drugs. Conclusion. The study formulated a set of proposals for the standardization of digital services of online pharmacies on the basis of regulations governing the activities of phar- macy organizations. A model for improving sites is proposed, which provides for the expansion of functionality and the improvement of the quality of pharmaceu- tical assistance in the online trade of drugs and other pharmacy products, reducing the time and simplifying the procedure for ordering and purchasing them. The ad- vantage provided by the given set of criteria is the possibility of obtaining online pharmaceutical advice on the selection, use and storage of medicinal products, the pharmacological compatibility of medicinal products, the possibility of choosing analogues of medicinal products, taking into account the price and expiration date, as well as the ability to verify the authenticity of the medicinal product by labeling. The implementation of a set of proposals makes it possible to eliminate the short- comings inherent in online pharmacies at the moment and improve the quality of pharmaceutical services to the population in accordance with the legislative acts of the Russian Federation and the best practices of pharmaceutical activity.